SOPHiA GENETICS’ AI-based platform helps healthcare professionals make sense of genomic and radiomic data while sharing their knowledge through the world’s largest network of institutions, supporting them in their decision-making to improve diagnosis and treatment of cancer and rare diseases. SOPHiA GENETICS’ solutions are democratising data-driven medicine, bringing precision medicine and targeted therapies to more patients in 85 countries.

The company completed its initial public offering in July, 2021, and is registered under the ticker Nasdaq:SOPH.